CATEGORIES: Clinical Trials | Research

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) Calling CMT1A Patients Ages 18-75

by | Sep 1, 2020 | 2 comments

This study is a new international research project funded by the National Institutes of Health (NIH) called Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT). Dr. David Herrmann at the University of Rochester is the study’s Principal Investigator. There are 3 participating centers in the USA. 

※ University of Rochester, NY (Dr. David Herrmann, shown in photo below) 

※ University of Pennsylvania, PA (Dr. Steve Scherer) recruitment completed

※ University of Iowa, IA (Dr. Mike Shy) 

This study is enrolling people with CMT1A who are aged 18-75. 

The purpose of this study is to determine the best way to measure the progression of Charcot-Marie-Tooth Disease Type 1A (CMT1A) over time. This study is important to help us to prepare for clinical trials. We are looking at new ways of measuring changes in CMT1A progression over a short period of time and assessing their usefulness in measuring effects of treatments in future clinical trials.  In addition to measurements that are currently used to measure progression of CMT1A such as strength and sensation, this study would also include the following: 

※ Two questionnaires (the CMT Health Index and Overall Neuropathy Limitation Scale) that explore how you think CMT1A affects you

※ CMT Functional Outcome Measure (CMT-FOM) which assesses balance, walking, standing up from sitting in a chair, and manual dexterity 

※ We will also test your ability to feel nylon monofilaments (like fishing line) and photographing a small area of your hand using a non-invasive microscope that can look into the skin and see nerve endings 

※ Nerve conduction studies on one arm and one leg 

※ For some participants, an MRI scan of your lower leg muscles The study visits are approximately 4 hours (with an additional hour for optional MRI). 

The study visits are at 6-12 month intervals for up to 3 years. Participants will receive an honorarium and reimbursement of qualified travel expenses.  For more information about participating, please contact:   

University of Rochester 

Steffen Behrens-Spraggins (585) 275-5760 

Steffen_Behrens-spraggins@URMC.Rochester.edu   

University of Iowa 

Alexa Bacha (319) 467-5006 

[email protected]

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Join the conversation

Leave a Comment

2 Comments

  1. Dr. Roberta DeLuca

    My husband has CMT. I was totally unaware there was a community! We live in Central California and could be interested in some help or studies.

    Reply
  2. Roxanne

    HI there.
    Are there any clinical trials or research centres in South Africa.

    Reply

Leave a Reply to Roxanne Cancel reply

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news